

Claudia Sala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9111305/publications.pdf>

Version: 2024-02-01

48
papers

3,198
citations

201385

27
h-index

223531

46
g-index

53
all docs

53
docs citations

53
times ranked

4652
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibodies, epicenter of SARS-CoV-2 immunology. <i>Cell Death and Differentiation</i> , 2021, 28, 821-824.	5.0	9
2	Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. <i>Cell</i> , 2021, 184, 1821-1835.e16.	13.5	180
3	Multicenter analysis of sputum microbiota in tuberculosis patients. <i>PLoS ONE</i> , 2020, 15, e0240250.	1.1	10
4	FasR Regulates Fatty Acid Biosynthesis and Is Essential for Virulence of <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Microbiology</i> , 2020, 11, 586285.	1.5	1
5	Vaccines as remedy for antimicrobial resistance and emerging infections. <i>Current Opinion in Immunology</i> , 2020, 65, 102-106.	2.4	11
6	Polarly Localized EccE ₁ Is Required for ESX-1 Function and Stabilization of ESX-1 Membrane Proteins in <i>Mycobacterium tuberculosis</i> . <i>Journal of Bacteriology</i> , 2020, 202, .	1.0	7
7	Host-Directed Therapies and Anti-Virulence Compounds to Address Anti-Microbial Resistant Tuberculosis Infection. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2688.	1.3	6
8	Editorial on Special Issue "Tuberculosis Drug Discovery and Development 2019". <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6069.	1.3	0
9	Promoter mutagenesis for fine-tuning expression of essential genes in <i>Mycobacterium tuberculosis</i> . <i>Microbial Biotechnology</i> , 2018, 11, 238-247.	2.0	13
10	EspL is essential for virulence and stabilizes EspE, EspF and EspH levels in <i>Mycobacterium tuberculosis</i> . <i>PLoS Pathogens</i> , 2018, 14, e1007491.	2.1	33
11	Essential Nucleoid Associated Protein mlHF (Rv1388) Controls Virulence and Housekeeping Genes in <i>Mycobacterium tuberculosis</i> . <i>Scientific Reports</i> , 2018, 8, 14214.	1.6	19
12	Rv3852 (H-NS) of <i>Mycobacterium tuberculosis</i> Is Not Involved in Nucleoid Compaction and Virulence Regulation. <i>Journal of Bacteriology</i> , 2017, 199, .	1.0	9
13	E _C forms a filamentous structure in the cell envelope of <i>Mycobacterium tuberculosis</i> and impacts ESX ₁ secretion. <i>Molecular Microbiology</i> , 2017, 103, 26-38.	1.2	77
14	The Inosine Monophosphate Dehydrogenase, GuaB2, Is a Vulnerable New Bactericidal Drug Target for Tuberculosis. <i>ACS Infectious Diseases</i> , 2017, 3, 5-17.	1.8	83
15	Transcription facilitated genome-wide recruitment of topoisomerase I and DNA gyrase. <i>PLoS Genetics</i> , 2017, 13, e1006754.	1.5	56
16	<i>Mycobacterium ulcerans</i> Mouse Model Refinement for Pre-Clinical Profiling of Vaccine Candidates. <i>PLoS ONE</i> , 2016, 11, e0167059.	1.1	12
17	Characterization of DprE1-Mediated Benzothiazinone Resistance in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6451-6459.	1.4	36
18	Genomic and transcriptomic analysis of the streptomycin-dependent <i>Mycobacterium tuberculosis</i> strain 18b. <i>BMC Genomics</i> , 2016, 17, 190.	1.2	18

#	ARTICLE	IF	CITATIONS
19	Mycobacterium tuberculosis Differentially Activates cGAS- and Inflammasome-Dependent Intracellular Immune Responses through ESX-1. <i>Cell Host and Microbe</i> , 2015, 17, 799-810.	5.1	341
20	Lansoprazole is an antituberculous prodrug targeting cytochrome bc1. <i>Nature Communications</i> , 2015, 6, 7659.	5.8	141
21	Bioluminescence for Assessing Drug Potency against Nonreplicating Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4012-4019.	1.4	30
22	CtrA Protein Rv3789 Is Required for Arabinosylation of Arabinogalactan in Mycobacterium tuberculosis. <i>Journal of Bacteriology</i> , 2015, 197, 3686-3697.	1.0	26
23	Whole-Genome Sequencing for Comparative Genomics and De Novo Genome Assembly. <i>Methods in Molecular Biology</i> , 2015, 1285, 1-16.	0.4	15
24	The PhoP-Dependent ncRNA Mcr7 Modulates the TAT Secretion System in Mycobacterium tuberculosis. <i>PLoS Pathogens</i> , 2014, 10, e1004183.	2.1	127
25	In Vitro and In Vivo Activities of Three Oxazolidinones against Nonreplicating Mycobacterium tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3217-3223.	1.4	53
26	Espl regulates the ESX-1 secretion system in response to ATP levels in Mycobacterium tuberculosis. <i>Molecular Microbiology</i> , 2014, 93, 1057-1065.	1.2	27
27	Assessing the essentiality of the decaprenylphospho- <i>d</i> -arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. <i>Molecular Microbiology</i> , 2014, 92, 194-211.	1.2	76
28	Assessing essentiality of transketolase in Mycobacterium tuberculosis using an inducible protein degradation system. <i>FEMS Microbiology Letters</i> , 2014, 358, 30-35.	0.7	8
29	The Phosphatidyl- <i>myo</i> -inositol Mannosyltransferase PimA Is Essential for Mycobacterium tuberculosis Growth In Vitro and In Vivo. <i>Journal of Bacteriology</i> , 2014, 196, 3441-3451.	1.0	37
30	Anticytolytic Screen Identifies Inhibitors of Mycobacterial Virulence Protein Secretion. <i>Cell Host and Microbe</i> , 2014, 16, 538-548.	5.1	83
31	High-resolution detection of DNA binding sites of the global transcriptional regulator GlxR in Corynebacterium glutamicum. <i>Microbiology (United Kingdom)</i> , 2013, 159, 12-22.	0.7	44
32	High-resolution transcriptome and genome-wide dynamics of RNA polymerase and NusA in Mycobacterium tuberculosis. <i>Nucleic Acids Research</i> , 2013, 41, 961-977.	6.5	41
33	Streptomycin-Starved Mycobacterium tuberculosis 18b, a Drug Discovery Tool for Latent Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5782-5789.	1.4	88
34	Genome-Wide Definition of the SigF Regulon in Mycobacterium tuberculosis. <i>Journal of Bacteriology</i> , 2012, 194, 2001-2009.	1.0	46
35	Towards a new tuberculosis drug: pyridomycin – nature's isoniazid. <i>EMBO Molecular Medicine</i> , 2012, 4, 1032-1042.	3.3	175
36	Virulence Regulator EspR of Mycobacterium tuberculosis Is a Nucleoid-Associated Protein. <i>PLoS Pathogens</i> , 2012, 8, e1002621.	2.1	115

#	ARTICLE	IF	CITATIONS
37	Tuberculosis drugs: new candidates and how to find more. <i>Future Microbiology</i> , 2011, 6, 617-633.	1.0	36
38	Sigma Factor F Does Not Prevent Rifampin Inhibition of RNA Polymerase or Cause Rifampin Tolerance in <i>Mycobacterium tuberculosis</i> . <i>Journal of Bacteriology</i> , 2010, 192, 5472-5479.	1.0	14
39	Simple Model for Testing Drugs against Nonreplicating <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4150-4158.	1.4	117
40	Development of a repressible mycobacterial promoter system based on two transcriptional repressors. <i>Nucleic Acids Research</i> , 2010, 38, e134-e134.	6.5	74
41	Genome-wide regulon and crystal structure of Blal (Rv1846c) from <i>Mycobacterium tuberculosis</i> . <i>Molecular Microbiology</i> , 2009, 71, 1102-1116.	1.2	61
42	Dissecting Regulatory Networks in Host-Pathogen Interaction Using ChIP-on-chip Technology. <i>Cell Host and Microbe</i> , 2009, 5, 430-437.	5.1	14
43	Benzothiazinones Kill <i>Mycobacterium tuberculosis</i> by Blocking Arabinan Synthesis. <i>Science</i> , 2009, 324, 801-804.	6.0	660
44	The <i>katG</i> mRNA of <i>Mycobacterium tuberculosis</i> and <i>Mycobacterium smegmatis</i> is processed at its 5' end and is stabilized by both a polypurine sequence and translation initiation. <i>BMC Molecular Biology</i> , 2008, 9, 33.	3.0	22
45	Bacteriophage P4 <i>sut1</i> : a mutation suppressing transcription termination. <i>Journal of General Virology</i> , 2007, 88, 1041-1047.	1.3	0
46	DNA replication in phage P4: Characterization of replicon II. <i>Plasmid</i> , 2006, 56, 216-222.	0.4	2
47	<i>Mycobacterium tuberculosis</i> FurA Autoregulates Its Own Expression. <i>Journal of Bacteriology</i> , 2003, 185, 5357-5362.	1.0	61
48	Transcriptional Regulation of <i>furA</i> and <i>katG</i> upon Oxidative Stress in <i>Mycobacterium smegmatis</i> . <i>Journal of Bacteriology</i> , 2001, 183, 6801-6806.	1.0	67